var data={"title":"Mometasone (oral inhalation): Pediatric drug information \t","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Mometasone (oral inhalation): Pediatric drug information \t</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/396571?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=mometasone-oral-inhalation-drug-information\" class=\"drug drug_general\">see &quot;Mometasone (oral inhalation): Drug information \t&quot;</a> and <a href=\"topic.htm?path=mometasone-oral-inhalation-patient-drug-information\" class=\"drug drug_patient\">see &quot;Mometasone (oral inhalation): Patient drug information \t&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9461865\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Asmanex 120 Metered Doses;</li>\n      <li>Asmanex 14 Metered Doses;</li>\n      <li>Asmanex 30 Metered Doses;</li>\n      <li>Asmanex 60 Metered Doses;</li>\n      <li>Asmanex 7 Metered Doses;</li>\n      <li>Asmanex HFA</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13935718\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Asmanex Twisthaler</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10502944\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Anti-inflammatory Agent</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Antiasthmatic</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Corticosteroid, Inhalant (Oral)</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Glucocorticoid</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10503024\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=mometasone-oral-inhalation-drug-information\" class=\"drug drug_general\">see &quot;Mometasone (oral inhalation): Drug information \t&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Asthma: Note:</b> Asmanex Twisthaler (110 mcg and 220 mcg Twisthaler) deliver 100 and 200 mcg mometasone furoate per actuation respectively; NAEPP uses doses based on delivery dose, while manufacturer recommended doses are based on inhaler amount. Maximum effects may not be evident for 1 to 2 weeks or longer; higher doses may provide additional asthma control in patients who do not respond adequately after 2 weeks of therapy. Doses should be titrated to the lowest effective dose once asthma is controlled.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Asmanex Twisthaler</i> (dry powder inhaler):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children 4 to 11 years (regardless of prior therapy): <b>Note:</b> Use 110 mcg inhaler: Oral inhalation (110 mcg/inhalation): Initial: 110 mcg once daily, administered in the evening. Maximum daily dose: 110 mcg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children &ge;12 years and Adolescents: Dosing based on previous asthma therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Patients previously treated with bronchodilators alone or with inhaled corticosteroids: Oral Inhalation (220 mcg/inhalation): Initial: 220 mcg once daily, administered in the evening; may increase dose after 2 weeks if adequate response not obtained. Maximum daily dose: 440 mcg/<b>day</b>; may be administered as 1 inhalation twice daily or 2 inhalations once daily in the evening</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Patients previously treated with oral corticosteroids: Oral Inhalation (220 mcg/inhalation): Initial: 440 mcg twice daily. Maximum daily dose: 880 mcg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Asmanex HFA: </i>Children &ge;12 years and Adolescents: Dosing based on previous asthma therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Patients previously treated with inhaled medium dose corticosteroid: Oral inhalation (100 mcg/inhalation): 200 mcg twice daily; maximum daily dose: 800 mcg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Patients previously treated with high-dose inhaled corticosteroids or oral corticosteroids: Oral inhalation (200 mcg/inhalation): 400 mcg twice daily; maximum daily dose: 800 mcg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Asthma Guidelines: </i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Global Initiative for Asthma Guidelines (GINA 2017): Dry powder inhaler (refers to Asmanex Twisthaler 110 mcg and 220 mcg strengths)</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Children 6 to 11 years:</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">&ldquo;Low&rdquo; dose: 110 mcg/day</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">&ldquo;Medium&rdquo; dose: &ge;220 to &lt;440 mcg/day</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">&ldquo;High&rdquo; dose: &ge;440 mcg/day</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Children &ge;12 years and Adolescents: Oral inhalation:</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">&ldquo;Low&rdquo; dose: 110 to 220 mcg/day</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">&ldquo;Medium&rdquo; dose: &gt;220 to 440 mcg/day</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">&ldquo;High&rdquo; dose: &gt;440 mcg/day</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">National Asthma Education and Prevention Program (NAEPP 2007): Dry powder inhaler (refers to Asmanex Twisthaler 220 mcg strength): Children &ge;12 years and Adolescents: Oral inhalation:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&quot;Low&quot; dose: 200 mcg/day</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&quot;Medium&quot; dose: 400 mcg/day</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&quot;High&quot; dose: &gt;400 mcg/day</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Conversion from oral systemic corticosteroids to orally inhaled corticosteroids:</b> When using mometasone oral inhalation to help reduce or discontinue oral corticosteroid therapy, begin prednisone taper after at least 1 week of mometasone inhalation therapy; prednisone should be tapered slowly (ie, no faster than 2.5 mg/day on a weekly basis); monitor patients for signs of asthma instability and adrenal insufficiency; decrease mometasone to lowest effective dose after prednisone reduction is complete.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult: <b>Asthma:</b> Oral inhalation: <b>Note:</b> Dosage forms of Asmanex Twisthaler (110 mcg and 220 mcg Twisthaler) deliver 100 and 200 mcg mometasone furoate per actuation respectively. Maximum effects may not be evident for 1 to 2 weeks or longer; higher doses may provide additional asthma control in patients who do not respond adequately after 2 weeks of therapy. Doses should be titrated to the lowest effective dose.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Previous therapy:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Bronchodilators: Asmanex Twisthaler: Initial: 220 mcg daily (maximum: 440 mcg/day); may be given in the evening or in divided doses twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Inhaled corticosteroids:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Asmanex HFA: Maximum: 400 mcg twice daily (800 mcg/day)</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Inhaled medium-dose corticosteroids: Asmanex HFA 100 mcg inhaler: 200 mcg twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Inhaled high-dose corticosteroids: Asmanex HFA 200 mcg inhaler: 400 mcg twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Asmanex Twisthaler: Initial: 220 mcg daily (maximum: 440 mcg/day); may be given in the evening or in divided doses twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral corticosteroids: <b>Note:</b> Prednisone should be reduced slowly (ie, no faster than 2.5 mg daily on a weekly basis), beginning after at least 1 week of mometasone use</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Asmanex HFA: Initial: 400 mcg twice daily (maximum: 800 mcg/day)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Asmanex Twisthaler: Initial: 440 mcg twice daily (maximum: 880 mcg/day)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Asthma Guidelines:</i> National Asthma Education and Prevention Program guidelines (NAEPP 2007): Dry powder inhaler (refers to Asmanex 200 mcg strength available in US). <b>Note:</b> 220 mcg inhaler delivers 200 mcg mometasone furoate per actuation; NAEPP uses doses based on delivery, while manufacturer recommended doses are based on inhaler amount.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&ldquo;Low&rdquo; dose: 200 mcg daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&ldquo;Medium&rdquo; dose: 400 mcg daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&ldquo;High&rdquo; dose: &gt;400 mcg daily</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment: </b>There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment: </b>There are no dosage adjustments provided in the manufacturer's labeling (has not been studied); however, mometasone exposure may increase with severity of hepatic impairment.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9461992\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Aerosol, Inhalation, as furoate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Asmanex HFA: 100 mcg/actuation (13 g); 200 mcg/actuation (13 g)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Aerosol Powder Breath Activated, Inhalation, as furoate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Asmanex 120 Metered Doses: 220 mcg/INH (1 ea) [contains milk protein]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Asmanex 14 Metered Doses: 220 mcg/INH (1 ea) [contains milk protein]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Asmanex 30 Metered Doses: 110 mcg/INH (1 ea); 220 mcg/INH (1 ea) [contains milk protein]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Asmanex 60 Metered Doses: 220 mcg/INH (1 ea) [contains milk protein]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Asmanex 7 Metered Doses: 110 mcg/INH (1 ea) [contains milk protein]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9461868\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46518754\" class=\"block dosfc drugH1Div\"><span class=\"drugH1\">Dosage Forms Considerations</span><p>(For additional information <a href=\"topic.htm?path=mometasone-oral-inhalation-drug-information\" class=\"drug drug_general\">see &quot;Mometasone (oral inhalation): Drug information \t&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">Asmanex HFA inhaler delivers 120 actuations.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10503026\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Asmanex Twisthaler (Dry powder inhaler): Remove inhaler from foil pouch; write date on cap label. Keep inhaler upright while removing cap, twisting in a counterclockwise direction; lifting the cap loads the device with the medication. Exhale fully prior to bringing the inhaler up to the mouth. Place inhaler in mouth, while holding it in a horizontal position. Close lips around the mouthpiece and inhale quickly and deeply. Remove the inhaler from your mouth and hold your breath for about 10 seconds, if possible. Do not exhale into inhaler. Wipe the mouthpiece dry and replace the cap immediately after each inhalation; rotate fully until click is heard. Rinse mouth with water (without swallowing) after inhalation to decrease chance of oral candidiasis. Avoid contact of the inhaler with any liquids; do not wash; wipe with dry cloth or tissue if needed. Discard the inhaler 45 days after opening foil pouch or when dose counter reads &quot;00.&quot;</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Asmanex HFA (Metered dose inhaler): Shake well prior to use; administer as 2 inhalations twice daily (morning and evening). Prime the inhaler before first use by releasing 4 test sprays into the air, away from the face, shaking well before each spray. If the inhaler has not been used for more than 5 days, prime the inhaler again with 4 test sprays. Rinse mouth with water without swallowing (decreases the chance of oral candidiasis). Do not wash inhaler with water; clean mouthpiece using a dry cloth every 7 days and discard inhaler after the counter reaches &ldquo;0&rdquo;.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9461928\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Asmanex HFA: Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Do not puncture. Do not use or store near heat or open flame. Exposure to temperatures above 120&deg;F may cause bursting. Discard when the dose counter reads &ldquo;0&quot;.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Asmanex Twisthaler: Store at 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Discard when oral dose counter reads &quot;00&quot; (or 45 days after opening the foil pouch).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10502964\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Maintenance treatment of asthma as prophylactic therapy (Asmanex Twisthaler: FDA approved in ages &ge;4 years and adults; Asmanex HFA: FDA approved in &ge;12 years and adults); <b>NOT</b> indicated for the relief of acute bronchospasm</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9461919\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Central nervous system: Depression, fatigue, headache, pain</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Gastrointestinal: Abdominal pain, anorexia, dyspepsia, gastroenteritis, nausea, oral candidiasis, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Genitourinary: Dysmenorrhea, urinary tract infection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hematologic &amp; oncologic: Bruise</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Infection: Infection, influenza</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Neuromuscular &amp; skeletal: Arthralgia, back pain, musculoskeletal pain, myalgia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Ophthalmic: Increased intraocular pressure</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Otic: Otalgia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Respiratory: Allergic rhinitis (more common in adolescents &amp; adults), bronchitis, dry throat, epistaxis, flu-like symptoms, nasal discomfort, nasopharyngitis, pharyngitis, sinus congestion, sinusitis, upper respiratory tract infection, voice disorder</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Miscellaneous: Fever</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Rare but important or life-threatening: Cataract, exacerbation of asthma, glaucoma, growth suppression, hypersensitivity</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9461914\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to mometasone or any component of the formulation; hypersensitivity to milk proteins (Asmanex Twisthaler only); primary treatment of status asthmaticus or other acute episodes of asthma for which intensive measures are required</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Documentation of allergenic cross-reactivity for corticosteroids is limited. However, because of similarities in chemical structure and/or pharmacologic actions, the possibility of cross-sensitivity cannot be ruled out with certainty.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in US labeling): Untreated systemic fungal, bacterial, viral, or parasitic infections; active or quiet tuberculosis infection of the respiratory tract; ocular herpes simplex</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9461915\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Adrenal suppression: May cause hypercortisolism or suppression of hypothalamic-pituitary-adrenal (HPA) axis, particularly in younger children or in patients receiving high doses for prolonged periods. HPA axis suppression may lead to adrenal crisis. Withdrawal and discontinuation of a corticosteroid should be done slowly and carefully. Particular care is required when patients are transferred from systemic corticosteroids to inhaled products due to possible adrenal insufficiency or withdrawal from steroids, including an increase in allergic symptoms. Adult patients receiving &gt;20 mg per day of prednisone (or equivalent) may be most susceptible. Fatalities have occurred due to adrenal insufficiency in asthmatic patients during and after transfer from systemic corticosteroids to aerosol steroids; aerosol steroids do <b>not</b> provide the systemic steroid needed to treat patients having trauma, surgery, or infections. Select surgical patients on long-term, high-dose, inhaled corticosteroids should be given stress doses of hydrocortisone intravenously during the surgical period and the dose reduced rapidly within 24 hours after surgery (NAEPP 2007).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bronchospasm: Paradoxical bronchospasm may occur with wheezing after inhalation; may be life-threatening. If this occurs, stop steroid and treat with a fast-acting bronchodilator.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity: Reactions including allergic dermatitis, anaphylaxis, angioedema, bronchospasm, flushing, pruritus, rash, and urticaria have been reported; if these symptoms occur, discontinue use.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Immunosuppression: Prolonged use of corticosteroids may increase the incidence of secondary infection, mask acute infection (including fungal infections), prolong or exacerbate viral infections, or limit response to vaccines. Avoid use if possible in patients with ocular herpes; active or quiescent tuberculosis infections of the respiratory tract; or untreated viral, fungal, or bacterial or parasitic systemic infections. Exposure to chickenpox or measles should be avoided; if the patient is exposed to chickenpox, prophylaxis with varicella zoster immune globulin or pooled intravenous immunoglobulin may be indicated; if chickenpox develops, treatment with antiviral agents may be considered. If exposure to measles, prophylaxis with pooled intramuscular immunoglobulin may be indicated.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Kaposi sarcoma: Prolonged treatment with corticosteroids has been associated with the development of Kaposi sarcoma (case reports); if noted, discontinuation of therapy should be considered (Goedert 2002).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Oral candidiasis: Local oropharyngeal <i>Candida</i> infections have been reported; if this occurs, treat appropriately while continuing mometasone therapy. Patients should be instructed to rinse mouth after each use.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Psychiatric disturbances: Corticosteroid use may cause psychiatric disturbances, including depression, euphoria, insomnia, mood swings, and personality changes. Preexisting psychiatric conditions may be exacerbated by corticosteroid use.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Vasculitis: Rare cases of vasculitis (eosinophilic granulomatosis with polyangiitis [formerly known as Churg-Strauss]) or other systemic eosinophilic conditions can occur; often associated with decrease and/or withdrawal of oral corticosteroid therapy following initiation of inhaled corticosteroid.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Asthma: Supplemental steroids (oral or parenteral) may be needed during stress or severe asthma attacks. Not to be used in status asthmaticus or for the relief of acute bronchospasm.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bone mineral density: Use with caution in patients with major risk factors for decreased bone mineral count such as prolonged immobilization, family history of osteoporosis, or chronic use of drugs that can reduce bone mass (eg, anticonvulsants, oral corticosteroids); long-term use of inhaled corticosteroids have been associated with decreases in bone mineral density.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular disease: Use with caution in patients with heart failure; long-term corticosteroid use has been associated with fluid retention and hypertension.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Diabetes: Use with caution in patients with diabetes mellitus; corticosteroids may alter glucose production/regulation leading to hyperglycemia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; GI disease: Use corticosteroids with caution in patients with GI diseases (diverticulitis, peptic ulcer, ulcerative colitis) due to perforation risk.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment, including cirrhosis; long-term corticosteroid use has been associated with fluid retention.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Myasthenia gravis: Use with caution in patients with myasthenia gravis; exacerbation of symptoms has occurred especially during initial treatment with corticosteroids.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Myocardial infarct (MI): Use with caution following acute MI; corticosteroids have been associated with myocardial rupture.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Ocular disease: Use with caution in patients with cataracts and/or glaucoma; increased intraocular pressure, open-angle glaucoma, and cataracts have occurred with prolonged use. Consider routine eye exams in chronic users.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment; fluid retention may occur with long-term corticosteroid use.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Seizure disorders: Use with caution in patients with a history of seizure disorder; seizures have been reported with adrenal crisis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Thyroid disease: Changes in thyroid status may necessitate dosage adjustments; metabolic clearance of corticosteroids increases in hyperthyroid patients and decreases in hypothyroid patients.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatrics: Orally inhaled corticosteroids may cause a reduction in growth velocity in pediatric patients (~1 cm per year [range, 0.3 to 1.8 cm per year] and related to dose and duration of exposure). To minimize the systemic effects of orally inhaled corticosteroids, each patient should be titrated to the lowest effective dose. Growth should be routinely monitored in pediatric patients.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Lactose: Asmanex Twisthaler: May contain lactose; very rare anaphylactic reactions have been reported in patients with severe milk protein allergy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Prior to use, the dose and duration of treatment should be based on the risk versus benefit for each individual patient. In general, use the smallest effective dose for the shortest duration of time to minimize adverse events. Short-acting beta-2 agonist (eg, albuterol) should be used for acute symptoms and symptoms occurring between treatments.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Discontinuation of systemic corticosteroid therapy: Withdraw systemic corticosteroid therapy with gradual tapering of dose; consider reducing the daily prednisone dose by 2.5 mg on a weekly basis beginning after at least 1 week of inhalation therapy. Monitor lung function, beta-agonist use, asthma symptoms, and for signs and symptoms of adrenal insufficiency (fatigue, lassitude, weakness, nausea and vomiting, hypotension) during withdrawal.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Transfer to oral inhaler: When transferring to oral inhaler, previously suppressed allergic conditions (eg, rhinitis, conjunctivitis, eczema, arthritis, eosinophilic conditions) may be unmasked.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9461922\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP3A4 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9461923\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=16022&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Aldesleukin: Corticosteroids may diminish the antineoplastic effect of Aldesleukin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amphotericin B: Corticosteroids (Orally Inhaled) may enhance the hypokalemic effect of Amphotericin B. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ceritinib: Corticosteroids may enhance the hyperglycemic effect of Ceritinib. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Corticorelin: Corticosteroids may diminish the therapeutic effect of Corticorelin. Specifically, the plasma ACTH response to corticorelin may be blunted by recent or current corticosteroid therapy. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Corticosteroids (Orally Inhaled). Management: Orally inhaled fluticasone propionate with a strong CYP3A4 inhibitor is not recommended.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: Corticosteroids may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Desmopressin: Corticosteroids (Orally Inhaled) may enhance the hyponatremic effect of Desmopressin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hyaluronidase: Corticosteroids may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving corticosteroids (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Loop Diuretics: Corticosteroids (Orally Inhaled) may enhance the hypokalemic effect of Loop Diuretics. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Loxapine: Agents to Treat Airway Disease may enhance the adverse/toxic effect of Loxapine. More specifically, the use of Agents to Treat Airway Disease is likely a marker of patients who are likely at a greater risk for experiencing significant bronchospasm from use of inhaled loxapine.  Management: This is specific to the Adasuve brand of loxapine, which is an inhaled formulation.  This does not apply to non-inhaled formulations of loxapine.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ritodrine: Corticosteroids may enhance the adverse/toxic effect of Ritodrine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thiazide and Thiazide-Like Diuretics: Corticosteroids (Orally Inhaled) may enhance the hypokalemic effect of Thiazide and Thiazide-Like Diuretics. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9461910\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Uncontrolled asthma is associated with adverse events on pregnancy (increased risk of perinatal mortality, preeclampsia, preterm birth, low birth weight infants). Poorly controlled asthma or asthma exacerbations may have a greater fetal/maternal risk than what is associated with appropriately used asthma medications (ACOG 2008; GINA 2016).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Inhaled corticosteroids are recommended for the treatment of asthma during pregnancy (ACOG 2008; GINA 2016; Namazy 2016). Pregnant females adequately controlled on mometasone for asthma may continue therapy; if initiating treatment during pregnancy, use of an agent with more data in pregnant females may be preferred (Namazy 2016).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10503065\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Monitor growth in pediatric patients (via stadiometry). Check mucous membranes for signs of fungal infection. Monitor asthma symptoms, FEV<sub>1</sub>, peak flow and/or other pulmonary function tests; HPA axis suppression; ocular effects (eg, cataracts, increased intraocular pressure, glaucoma); bone mineral density</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9461929\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">May depress the formation, release, and activity of endogenous chemical mediators of inflammation (kinins, histamine, liposomal enzymes, prostaglandins). Leukocytes and macrophages may have to be present for the initiation of responses mediated by the above substances. Inhibits the margination and subsequent cell migration to the area of injury, and also reverses the dilatation and increased vessel permeability in the area resulting in decreased access of cells to the sites of injury.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9461931\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: Maximum effects may not be evident for &ge;1 to 2 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Duration after discontinuation: Several days or more</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: &lt;1%; clinical effects are due to direct local effect, rather than systemic absorption</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: V<sub>d</sub>: 152 L</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: 98% to 99%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Extensive in the liver to multiple metabolites; no major metabolites are detectable in the plasma; in vitro incubation studies identified one minor metabolite, 6 Beta-hydroxymometasone furoate, formed via cytochrome P450 CYP3A4 pathway </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: Single dose: &lt;1%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: Mean: 5 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, plasma: 0.5 to 2.5 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Feces (~74%), urine (~8%)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9461994\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Aerosol</b> (Asmanex HFA Inhalation)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mcg/ACT (13 g): $229.63</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mcg/ACT (13 g): $269.88</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Aerosol powder</b> (Asmanex 120 Metered Doses Inhalation)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">220 mcg/INH (1): $386.52</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Aerosol powder</b> (Asmanex 14 Metered Doses Inhalation)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">220 mcg/INH (1): $88.75</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Aerosol powder</b> (Asmanex 30 Metered Doses Inhalation)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">110 mcg/INH (1): $212.87</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">220 mcg/INH (1): $229.86</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Aerosol powder</b> (Asmanex 60 Metered Doses Inhalation)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">220 mcg/INH (1): $269.74</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Aerosol powder</b> (Asmanex 7 Metered Doses Inhalation)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">110 mcg/INH (1): $88.75</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23669751\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Asmaneks (UA);</li>\n      <li>Asmanex (AT, CR, CZ, DK, DO, EE, FI, GR, GT, HN, HU, IE, JP, NI, NL, NO, PA, RO, SG, SV, VE);</li>\n      <li>Asmanex Twisthaler (AE, AU, BH, CH, DE, ES, FR, GB, HK, JO, KR, KW, NZ, PL, PT, QA, RU, SE, SI, SK, TR, VN);</li>\n      <li>Hexaler (AR);</li>\n      <li>Meclonex (BD);</li>\n      <li>Momeson (BD)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    ACOG Committee on Practice Bulletins-Obstetrics, &quot;ACOG Practice Bulletin: Clinical Management Guidelines for Obstetrician-Gynecologists Number 90, February 2008: Asthma in Pregnancy,&quot; <i>Obstet Gynecol</i>, 2008, 111(2 Pt 1):457-64.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mometasone-oral-inhalation-pediatric-drug-information/abstract-text/18238988/pubmed\" target=\"_blank\" id=\"18238988\">18238988</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Asmanex HFA (mometasone furoate) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co; July 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Asmanex Twisthaler (mometasone furoate) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co; September 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bakhireva LN, Jones KL, Schatz M, et al, &ldquo;Asthma Medication Use in Pregnancy and Fetal Growth,&rdquo; <i>J Allergy Clin Immunol</i>, 2005, 116(3):503-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mometasone-oral-inhalation-pediatric-drug-information/abstract-text/16159616/pubmed\" target=\"_blank\" id=\"16159616\">16159616</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention, 2017. Available at http://ginasthma.org/. Updated 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Goedert JJ, Vitale F, Lauria C, et al. Risk factors for classical Kaposi's sarcoma. <i>J Natl Cancer Inst</i>. 2002;94(22):1712-1718.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mometasone-oral-inhalation-pediatric-drug-information/abstract-text/12441327/pubmed\" target=\"_blank\" id=\"12441327\">12441327</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Namazy J, Schatz M, Long L, et al, &ldquo;Use of Inhaled Steroids by Pregnant Asthmatic Women Does Not Reduce Intrauterine Growth,&rdquo; <i>J Allergy Clin Immunol</i>, 2004, 113(3):427-32.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mometasone-oral-inhalation-pediatric-drug-information/abstract-text/15007341/pubmed\" target=\"_blank\" id=\"15007341\">15007341</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    National Asthma Education and Prevention Program (NAEPP), &quot;Expert Panel Report 3 (EPR-3): Guidelines for the Diagnosis and Management of Asthma,&quot; <i>Clinical Practice Guidelines</i>, National Institutes of Health, National Heart, Lung, and Blood Institute, NIH Publication No. 08-4051, prepublication 2007. Available at <a href=\"http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm\" target=\"_blank\">http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    National Asthma Education and Prevention Program (NAEPP) Working Group Report on &ldquo;Managing Asthma During Pregnancy: Recommendations for Pharmacologic Treatment,&rdquo; National Institutes of Health, National Heart, Lung, and Blood Institute, NIH Publication No. 05-5236, March 2005. Available at <a href=\"http://www.nhlbi.nih.gov/health/prof/lung/asthma/astpreg/astpreg_full.pdf\" target=\"_blank\">http://www.nhlbi.nih.gov/health/prof/lung/asthma/astpreg/astpreg_full.pdf</a></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 16022 Version 105.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F9461865\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F13935718\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F10502944\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F10503024\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F9461992\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F9461868\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms Considerations\" href=\"#F46518754\" class=\"outlineLink\">Dosage Forms Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F10503026\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F9461928\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F10502964\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F9461919\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F9461914\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F9461915\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F9461922\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F9461923\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F9461910\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F10503065\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F9461929\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F9461931\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F9461994\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F23669751\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/16022|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=mometasone-oral-inhalation-drug-information\" class=\"drug drug_general\">Mometasone (oral inhalation): Drug information \t</a></li><li><a href=\"topic.htm?path=mometasone-oral-inhalation-patient-drug-information\" class=\"drug drug_patient\">Mometasone (oral inhalation): Patient drug information \t</a></li></ul></div></div>","javascript":null}